Key result
Higher American Society of Anesthesiology classification was associated with worse 5-year cancer-specific survival (95.7% for ASA 1, 71.1% for ASA 2, and 39.8% for ASA 3; p=0.007).
Why the study?
Does the American Society of Anesthesiology (ASA) classification predict survival in patients with renal cell carcinoma undergoing nephrectomy?
Cohort (n=145)
Does the American Society of Anesthesiology (ASA) classification predict survival in patients with renal cell carcinoma undergoing nephrectomy?
The ASA classification can serve as a significant prognostic factor for cancer-specific and overall survival in patients undergoing nephrectomy for renal cell carcinoma.
ASA class may inform prognosis after RCC nephrectomy; extends prognostic evidence but leaves open prospective validation.
OBJECTIVES: We analyzed whether the American Society of Anesthesiology (ASA) classification could be used as a prognostic factor in renal cell carcinoma. METHODS: ASA classification's impact on cancer-specific survival (CSS) and on overall survival in 145 patients submitted to radical or partial nephrectomy was evaluated, and was compared with clinicopathological variables. RESULTS: CSS was influenced by ASA in uni- and multivariate analyses. Five-year CSS was 95.7, 71.1 and 39.8% for ASA 1, ASA 2 and ASA 3, respectively (p = 0.007). The ASA classification influenced the overall survival too (p < 0.001). When 18 patients with metastases were excluded, the CSS was 95.7, 83.9 and 42.9% for ASA 1, ASA 2 and ASA 3, respectively (p = 0.001). ASA 3 patients had ten times more metastases than ASA1 patients and two times more than ASA 2 patients (p = 0.001). ASA 3 patients had fewer incidental tumors (p = 0.043) than ASA 2 and 3 patients. CONCLUSION: In this series, the ASA classification could be used as a prognostic factor in renal cell carcinoma.
No takes yet. Share an insight, caveat, or question.
Zéqui et al. (2010) conducted a cohort in Renal cell carcinoma (n=145). American Society of Anesthesiology (ASA) classification vs. Lower ASA classification was evaluated on Cancer-specific survival (CSS) (p=0.007). Higher American Society of Anesthesiology classification was associated with worse 5-year cancer-specific survival (95.7% for ASA 1, 71.1% for ASA 2, and 39.8% for ASA 3; p=0.007).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: